Our proprietary discovery platform
Glymphatic function — the brain’s natural waste clearance system — depends on three key physiological processes: sleep EEG state, cerebral vascular function, and astrocyte regulation of brain interstitial resistance. Applied Cognition’s proprietary discovery platform is uniquely capable of directly measuring all three and is the first to measure astrocyte modulation in humans. Our research has shown that targeting a single physiological pathway is not sufficient to meaningfully enhance glymphatic function. In contrast, simultaneous engagement of all three, as achieved with our lead therapeutic asset, has demonstrated substantial improvements in glymphatic activity, leading to the clearance of amyloid and tau proteins from the human brain.
Engaging all three key physiologies was required to increase waste clearance
Advancing Brain Health Through Glymphatic Modulation
Restoring glymphatic function offers a promising new path for addressing neurodegenerative diseases. Most of these diseases involve multiple misfolded proteins — including beta-amyloid, tau, alpha-synuclein, and TDP-43 — which coexist and collectively drive disease progression. Existing therapies, such as monoclonal antibodies, typically target a single misfolded protein, while approaches aimed at reducing protein production, such as gamma-secretase modulators, often disrupt natural physiology, complicating therapeutic outcomes. Our therapeutic strategy focuses on revitalizing the brain’s natural waste clearance system.
